CAMBIUM BIO LIMITED — Investor Presentation 2021

Mar 2, 2021

==> picture [160 x 33] intentionally omitted <==

ASX Announcement

3 March 2021

Regeneus Company Update Investor Webcast Presentation

Regeneus Ltd (ASX: RGS) ( Regeneus or the Company ), a clinical-stage regenerative medicine company, today advises it has released an updated investor presentation.

The presentation will be delivered to investors by CEO Karolis Rosickas during Regeneus’ Company Update Investor Webcast taking place at 11:00am Australian Eastern Daylight Time (AEDT) this morning via Zoom.

To register for the webcast, please follow this link: https://us02web.zoom.us/webinar/register/WN_YyKYF3USS0WusNbNBlafAQ

Registered participants will receive a confirmation email containing the Zoom access link and alternative phone dial-in details.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

Investor and Media Contact

This announcement was authorised by WE Communications the Board of Directors of Regeneus Ltd T: (03) 8866 1200 E: WE-AURegeneus@we-worldwide.com

2 Paddington Street, Paddington, NSW 2021 Ph: +61 2 9499 8010 • www.regeneus.com.au • ABN 13 127 035 358

==> picture [189 x 30] intentionally omitted <==

==> picture [960 x 186] intentionally omitted <==

Company update presentation

Developing next generation pain management and inflammation therapeutics

Regeneus Ltd (ASX:RGS)

03 March 2021

Disclaimer

Summary Information: This Presentation contains summary information about the current activities of Regeneus as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete. This Presentation does not purport to contain all the information that an investor should consider when making an investment decision nor does it contain all the information which would be required in a disclosure document or prospectus prepared in accordance with the requirements of the Corporations Act. It should be read in conjunction with Regeneus’ other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au. Neither Regeneus nor its directors, employees or advisers give any warranties in relation to the statements and information in this Presentation.

Not an offer: This Presentation is for information purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or any other law (and will not be lodged with ASIC or any other regulator and is not approved by or registered with any regulator). The Presentation is not and should not be considered an offer or an invitation to acquire New Shares or any other financial products. This Presentation may not be released or distributed in the United States. This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any other jurisdiction in which such an offer would be illegal. The New Shares have not been, and will not be, registered under the U.S. Securities Act or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold, directly or indirectly, in the United States unless such New Shares have been registered under the U.S. Securities Act, or are offered and sold in a transaction exempt from, or not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws. The distribution of this Presentation in other jurisdictions outside Australia may also be restricted by law and any such restrictions should be observed. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Not financial product advice: This Presentation does not constitute financial product or investment advice (nor tax, accounting or legal advice) nor is it a recommendation to acquire New Shares and does not and will not form any part of any contract for the acquisition of New Shares. This Presentation has been prepared without taking into account the objectives, financial situation or needs of any particular investor. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek appropriate advice, including financial, legal and taxation advice appropriate to their jurisdiction. Regeneus is not licensed to provide financial product advice in respect of Regeneus’ shares or any other investment. Cooling off rights do not apply to the acquisition of New Shares.

Financial data: All dollar values are in Australian dollars (“A$”, “AUD”), unless indicated otherwise. Any pro forma financial information included in this Presentation is for illustrative purposes only and is not represented as being indicative of Regeneus’ views on its future financial condition and/ or performance. Any pro forma financial information has been prepared by Regeneus and may not have been prepared in accordance with the measurement and recognition requirements or the disclosure requirements, of applicable accounting standards and other mandatory requirements in Australia.

Future performance: This Presentation contains certain “forward looking statements”. Forward looking statements can generally be identified by the use of forward looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Regeneus, the outcome and effects of the Offers and the use of proceeds.

The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Regeneus, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Refer to the risks section of this Presentation for a summary of certain general and Regeneus specific risk factors that may affect Regeneus. There can be no assurance that actual outcomes will not differ materially from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements, including the risk factors set out in this Presentation. Investors should consider the forward looking statements contained in this Presentation in light of those disclosures. The forward looking statements are based on information available to Regeneus as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), Regeneus undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statements.

Effect of rounding: A number of figures, amounts, percentages, estimates, calculations of value and fractions in this Presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this Presentation.

Investment risks: An investment in New Shares is subject to investment and other known and unknown risks, some of which are beyond the control of Regeneus including possible loss of income and principal invested. Regeneus does not guarantee any particular rate of return or the performance of Regeneus, nor does it guarantee the repayment of capital from Regeneus or any particular tax treatment. In considering an investment in Regeneus shares, investors should have regard to (amongst other things) the risks outlined in this Presentation.

Disclaimer: To the maximum extent permitted by law, no representation or warranty, express or implied, is made as to the currency, accuracy, reliability or completeness of information in this Presentation and Regeneus and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents excludes and disclaims all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in the Offer and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. Regeneus and its advisors make no recommendations as to whether investors or their related parties should participate in the Offers. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice. Regeneus reserves the right to withdraw all or part of the Offers or vary the timetable for the Offers without notice.

==> picture [130 x 21] intentionally omitted <==

Confidential

2

Company overview

Background

• Regeneus (“RGS”) is a pioneer cell therapy company founded in Sydney in 2007

• The company went public (ASX:RGS) on the Australian Stock Exchange in 2013

• Two platform technologies leveraging proprietary IP in allogeneic adipose-derived mesenchymal stem cells (“MSC”) and their bioactive secretome (incl. cytokines, extracellular vehicles, miRNA)

• Successful Phase I trial of Progenza in knee osteoarthritis completed in 2017

• Signed Progenza collaboration and licensing partnership with Kyocera in Japan in 2020

• The company has filed or obtained over 80 patents in key geographies

Financial information	Financial information
Share price(02 Mar 2021)	A$ 0.115
Shares issued	300.3m
Market capitalisation	A$ 34.5m
Cash(as of 31 Dec 2020)	A$ 4.1m
Debt(as of 31 Dec 2020)	-
Enterprise value	A$ 30.4m

Experienced Board and management team

==> picture [71 x 72] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 70] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

Barry Sechos

Independent Chairman

Leo Lee

Non-Executive Director

John Chiplin

Non-Executive Director

Karolis Rosickas

Chief Executive Officer

Prof Graham Vesey

CSO & Executive Director

Dr Charlotte Morgan Dr Sinead Blaber Head of R&D Clinical Director

• President, Novartis Japan

• 20+ years experience as a director, business executive, and corporate lawyer

• 20+ years in pharma

• Former President of Allergan

• • Executive Director of and Merck Japan

• Sherman Group

• MD of Newstar Ventures

• Former CEO of three listed biotechnology, cancer immunotherapy and software companies

• 17 years experience in healthcare and technology

• Co-founder and CEO of SingCell and OME Health

• VP at HSBC M&A in London

• Regeneus co-founder

• 20+ years in managing • 10 years experience in product development and biotechnology industry innovation

• Co-founder of BTF, sold to BioMerieux in 2007

  • Directed Progenza STEP Trial

  • • PhD in Biotechnology • Joined Regeneus in 2009

• PhD in microbiology

• Adjunct Professor at Macquarie University • Joined Regeneus in 2012

==> picture [130 x 21] intentionally omitted <==

Confidential

3

Technology and products

==> picture [334 x 336] intentionally omitted <==

==> picture [129 x 21] intentionally omitted <==

4

Proprietary allogeneic mesenchymal stem cells and secretome platform

Mesenchymal stem cells

• Multipotent stem cells, which perform multiple functions in human body including direct differentiation, activation of resident stem cells and secretion of bioactive molecules (secretome)

Bioactive Secretome

• Bioactive molecules (cytokines, chemokines, growth factors, extracellular vesicles) secreted by MSCs

• • • Reduces inflammation and promotes tissue repair

• Improves functionality and viability of MSCs

==> picture [92 x 64] intentionally omitted <==

==> picture [69 x 34] intentionally omitted <==

The combination of MSCs and the bioactive MSC secretome exerts a more powerful therapeutic effect

Allogeneic cells

• Derived from a single donor

• Can be used in millions of patients

Adipose-derived

• Adipose contains 500-1000x more MSCs than bone marrow or other sources

Safe

• MSCs are immune-privileged cells, which escape patient’s immune system without the risk of rejection

• No genetic modification of cells

Established mechanism of action

• Immuno-modulatory properties of MSCs and bioactive secretome

• Direct cell differentiation

• Endogenous repair

==> picture [130 x 21] intentionally omitted <==

Confidential

5

How Regeneus platform technology is different?

MSCs / iPSCs only

• Generation 1.0 therapies

• Provide only limited functionality through differentiation and engraftment

Progenza MSCs and Bioactive Secretome

Extracellular vesicles (EVs)

• Novel, early-stage modality

• Expensive isolation and purification process

• Manufacturing scalability not proven yet  Still unknown mechanism of action of individual EVs

• Years away from regulatory approvals

• ✓ Secretome enhances viability and functionality of MSCs

• ✓ Secretome has independent immunomodulatory functions in inflamed environment

• ✓ Scalable and cost-effective manufacturing process

==> picture [130 x 21] intentionally omitted <==

Confidential

6

Established mechanism of action

PROGENZA

==> picture [900 x 327] intentionally omitted <==

----- Start of picture text -----

✓ Promotes endogenous
✓ Tissue repair ad-MSCs + Bioactive secretome cartilage repair
Soluble factors:
Cytokines
Chemokines
Growth factors
Differentiation
EVs: ↑ ECM protein secretion
Exosomes ↑ chondrocytes
Micro vesicles
Cell-cell contact
Macrophages NK cells
X
Immune cell Pro-inflammatory Anti-inflammatory Immature Mature ↓ pro-inflammatory cytokines
↑ anti-inflammatory cytokines
Lymphocytes Dendritic cells ↑ anti-catabolic factors
X ↑ matrix remodeling
✓ Immune modulation
↓ T- and B-cells Immature Mature
✓ Reduces inflammation and pain
----- End of picture text -----

The combination of MSCs and the bioactive MSC secretome in Progenza exerts a powerful therapeutic effect via repair and regeneration of endogenous joint tissues, reducing inflammation, modulation of the immune system and pain relief

==> picture [130 x 21] intentionally omitted <==

Confidential

7

Scalable product platforms

Multiple opportunities in pain and inflammation focused indications

==> picture [358 x 277] intentionally omitted <==

----- Start of picture text -----

Progenza
MSCs and
Secretome
United States Osteoarthritis
----- End of picture text -----

==> picture [263 x 263] intentionally omitted <==

----- Start of picture text -----

Orphan
diseases
Wound
healing
Sygenus
Cell free
Neuropathic Secretome
pain
Inflammatory
skin conditions
----- End of picture text -----

The product platforms are protected by a portfolio of 80+ patents covering multiple indications in key markets and expiring in late 2030s

==> picture [130 x 21] intentionally omitted <==

Confidential

8

Strong nonclinical and clinical data

Progenza

Osteoarthritis

Phase 1 (STEP)[1]

• Confirmed the Primary Endpoints of safety and tolerability at both low and high doses with a single injection

• Confirmed the Secondary Endpoints of efficacy:

• Pain : significant, rapid and sustained pain relief achieved via VAS and WOMAC Pain scores

• Cartilage : halting of disease progression 12-months post-treatment

==> picture [343 x 135] intentionally omitted <==

Progenza

Neuropathic pain

Preclinical

• Neuropathic pain is central in many disease indications (chronic lower back pain, trigeminal neuralgia, etc.) with no cure for the underlying causes

• Performed a study on Chronic Constriction Injury (CCI) model using rats and touch stimulator

• Demonstrated that a single injection of Progenza modifies disease in 14 days

Sygenus

Various indications

Preclinical

		Primary indication	Study Type	RoA	End Date	Subject #	Conclusions
		Topical safety	Safety & tolerability	Topical	Aug 2017	33 humans	✓Safety:Safe & well tolerated in acne prone patients
		Topical safety	Safety – RIPT	Topical	Oct 2017	50 humans	✓Safety:non-sensitizing and non-irritating
		Acne	Safety & efficacy	Topical	Jan 2018	30 humans	✓Safety:Safe and well tolerated ✓Efficacy: Significant improvement in acne measurements
		Age spots	Safety & efficacy	Topical	Mar 2018	36 humans	✓Safety:Safe and well tolerated ✓Efficacy: Significant reduction in age spot size andpigmentation

Source: (1) Kuah D, Sivell S, Longworth T, et al. Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study. J Transl Med 2018;16:49.

==> picture [130 x 21] intentionally omitted <==

Confidential

9

Established chemistry, manufacturing and controls (CMC) process

• Adipose-derived: adipose contains 500-1000 times more MSCs than bone marrow

Source material

• Allogeneic: multiple patients from a single donor. Improved product safety, potency, and consistency

• Rigorous donor screening process

• No genetic reprogramming of cells

Process overview

==> picture [69 x 57] intentionally omitted <==

Screen healthy donors based on strict cGCP and proprietary criteria

==> picture [30 x 57] intentionally omitted <==

==> picture [73 x 57] intentionally omitted <==

==> picture [59 x 57] intentionally omitted <==

==> picture [67 x 57] intentionally omitted <==

==> picture [85 x 48] intentionally omitted <==

Isolation, MCB and Expansion of cells to MSC long-term cryoSingle healthy adult Millions of doses from expansion of MSCs into manufacture millions of storage under GMP lipoaspirate single donor two-tiered cell bank MSC doses conditions

• Optimised, highly scalable manufacturing process of up to 300 million doses from a single donor

Advantages

• No source material or process variability, resulting in a homogenous final product

• Lower cost of goods (COGS) compared to autologous therapies, pluripotent stem cell therapies, or EV therapies

• Potential for further COGS reduction by transitioning to a 3D bioreactor-based manufacturing process

• Advanced process development work for manufacturing cGMP Master Cell Bank (MCB) with a US contract manufacturing organisation

Current status

• Final Product (FP) will be available in late 2021 for Progenza OA Phase 2 trials in the US and Australia

• Well characterised final product

• Established Quality Control (QC) and product release criteria

==> picture [130 x 21] intentionally omitted <==

Confidential

10

Pain and osteoarthritis market opportunity

==> picture [334 x 336] intentionally omitted <==

==> picture [129 x 21] intentionally omitted <==

11

Pain – large and growing problem

==> picture [443 x 305] intentionally omitted <==

----- Start of picture text -----

Prevalence of chronic pain [(1)]
Lower back pain 28.1%
Knee pain 19.5%
Severe headache or migraine 16.1%
Neck pain 15.1%
Shoulder pain 9.0%
Finger pain 7.6%
Hip pain 7.1%
0.0% 10.0% 20.0% 30.0%
----- End of picture text -----

==> picture [443 x 330] intentionally omitted <==

----- Start of picture text -----

Large addressable market
1.5bn
people worldwide suffering from pain [(2)]
50%
of patients report inadequate relief [(2)]
Knee Osteoarthritis
is pain and inflammation around the joint
from ‘wear and tear’ on the tissue
----- End of picture text -----

Figure: Age-adjusted prevalence rates of select causes of chronic pain in US adults Sources:

(1) Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research . Washington DC: The National Academies Press; 2011 (2) Chronic Pain and the Health of Populations. Boston University; 2017

==> picture [130 x 21] intentionally omitted <==

Confidential

12

Opportunity in knee osteoarthritis

Large addressable market

==> picture [29 x 28] intentionally omitted <==

==> picture [32 x 32] intentionally omitted <==

==> picture [32 x 32] intentionally omitted <==

==> picture [33 x 32] intentionally omitted <==

==> picture [32 x 32] intentionally omitted <==

==> picture [32 x 32] intentionally omitted <==

==> picture [32 x 32] intentionally omitted <==

==> picture [32 x 32] intentionally omitted <==

==> picture [900 x 144] intentionally omitted <==

----- Start of picture text -----

Worldwide United States Japan 5EU: DE, FR, GB, IT, ES
Patients 240m [(1)] 33m [(2)] 25m [(3)] 52m [(4)]
Market size [(4)] $3.5bn $2.6bn $330m $520m
----- End of picture text -----

Attractive market characteristics

==> picture [386 x 106] intentionally omitted <==

----- Start of picture text -----

Ageing population Increasing prevalence
of obesity
----- End of picture text -----

==> picture [392 x 106] intentionally omitted <==

----- Start of picture text -----

Dissatisfaction with No disease-modifying
existing treatments treatments
----- End of picture text -----

Sources:

• 1) Osteoarthritis Action Alliance, https://oaaction.unc.edu/oa-module/oa-prevalence-and-burden/ 2) Centers for Disease Control and Prevention (CDC)

• 3) Knee osteoarthritis only. Epidemiology of osteoarthritis in Japan : the ROAD study . 2011

• 4) Estimate for 2026. OpportunityAnalyzer: Osteoarthritis – Opportunity Analysis and Forecasts to 2026 . GlobalData

==> picture [130 x 21] intentionally omitted <==

Confidential

13

Current osteoarthritis treatment market

Current treatments only provide pain relief – not disease modification

less severe OA 50% of diagnosed and prevalent knee OA is moderate-severe ~5% cartilage loss per year as disease progresses

less invasive therapies

==> picture [38 x 38] intentionally omitted <==

==> picture [31 x 32] intentionally omitted <==

Lifestyle changes

Pain relief

Disease modification

Weight management, exercise Pharma: Paracetamol, non-steroidal and self-management anti-inflammatory drugs, opioids Injectables: Hyaluronic Acid or Corticosteroid Injections

No existing therapies

• Limited uptake  Target symptoms, not the cause

• Short-term adherence  Safety concerns  Short-term relief, limited efficacy  Risk of cartilage degradation with injectables

more severe OA more invasive therapies

Surgery & invasive procedure

Knee Replacement Revision Surgery Bone Marrow Stimulation Bone Realignment

• Invasive surgical intervention

• Long rehabilitation time  Limited prosthesis lifespan  Expensive

==> picture [130 x 21] intentionally omitted <==

Confidential

14

Where Progenza™fits in current osteoarthritis treatment market

Progenza addresses an unmet need in the current treatment market by providing disease modification and pain relief to address patient symptoms without having to undergo surgery and invasive procedures

less severe OA 50% of diagnosed and prevalent knee OA is moderate-severe ~5% cartilage loss per year as disease progresses

more severe OA

PROGENZA Long-term pain relief, DMOAD, delayed surgery Lifestyle changes Pain relief Disease modification Weight management, exercise Pharma: Paracetamol, non-steroidal and self-management anti-inflammatory drugs, opioids No existing Injectables: Hyaluronic Acid or therapies Corticosteroid Injections

Surgery & invasive procedure Knee Replacement Revision Surgery Bone Marrow Stimulation Bone Realignment

• Limited uptake  Target symptoms, not the cause ✓ Progenza - a safe, potent treatment before

• Short-term adherence  Safety concerns invasive surgical intervention is required  Short-term relief, limited efficacy  Risk of cartilage degradation with injectables

• Invasive surgical intervention

• Long rehabilitation time  Limited prosthesis lifespan  Expensive

==> picture [130 x 21] intentionally omitted <==

Confidential

15

Competitive landscape

Progenza is well positioned to become the first in class disease modifying therapy in knee osteoarthritis

Product	Progenza	Tanezumab	Fasinumab	AlloJoin	Cymerus	PPS	Invossa
Stage	P2	BLA	P3	P2	P3	P3	P3 (tbc)
Treats symptoms (pain)	✓	✓	✓	✓	unknown	✓/	✓
Potentially disease modifying	✓			unknown	unknown		✓
Safety profile	✓			✓	unknown	✓	
Cost of manufacturing	✓	✓	✓	✓	✓/	✓	

Source: GlobalData, internal company analysis

==> picture [130 x 21] intentionally omitted <==

Confidential

16

Value creation plan

==> picture [334 x 336] intentionally omitted <==

==> picture [129 x 21] intentionally omitted <==

17

Value drivers for Regeneus

Multiple levers to create shareholder value

• Licensing Independent Strategic

• and development M&A

• partnerships

• • Launch Progenza OA in partnership with • Prepare for Progenza OA Phase 2 trial in • Consider strategic exit to a large pharma or Kyocera in Japan the US a large cap biotech company

• Explore licensing opportunities for Progenza OA worldwide, ex-Japan

• Prepare for Progenza OA Phase 2 trial in Australia

• Progenza licensing opportunities in other • Grant opportunities in the US and Australia indications (e.g. neuropathic pain) • Sygenus co-development with medical

• • Licensing of Sygenus dermatology, cosmetics companies, and Government agencies

• Grant opportunities in the US and Australia

• Assess synergistic bolt-on acquisitions

• Research partnerships with Monash University, University of Adelaide, UTS, and A*STAR Singapore

==> picture [130 x 21] intentionally omitted <==

Confidential

18

Development pipeline

==> picture [909 x 404] intentionally omitted <==

----- Start of picture text -----

Platform Technology Indication Geography Stage Current status
Preclinical Phase 1 Phase 2 Phase 3 Approval
• Collaboration with Kyocera signed in 2020
2015 2017 2022 2024
Japan •
PMDA Conditional Approval expected in 2024
• FDA pre-IND consultations expected in Q2 2021
US 2015 2017 2022
Knee • Potential for RMAT designation and NIH funding
osteoarthritis
Australia 2015 2017 2022 • NHMRC grant application submitted, expected outcome in Q2 2021
• ATMP designation obtained in 2018
Europe 2015 2017 • Licensing options being explored
Neuropathic pain Global 2019 • Co-development and licensing options being explored
Burns, wounds
Neuropathic pain
• Expected Phase 1 trial in pain
Global 2018 2021
• Co-development and licensing options being explored
Inflammatory skin
conditions
Rare/orphan skin
diseases
Progenza
with bioactive secretome
Allogeneic adipose-derived MSCs
Sygenus secretome
MSC-derived bioactive
----- End of picture text -----

==> picture [130 x 21] intentionally omitted <==

Confidential

19

Collaboration and licensing agreement with Kyocera for osteoarthritis in Japan

==> picture [33 x 32] intentionally omitted <==

Expedited path to market in Japan

==> picture [197 x 42] intentionally omitted <==

Background

Deal

• Japan headquartered global diversified conglomerate

• The Collaboration and License Agreement was signed in August 2020

• Revenue $15.5bn, market capitalisation $23.6bn

• Life & Environment division manufactures medical products, including orthopaedic joint implants

• With no. 4 position in prosthetic knee market, Kyocera has an established network of orthopaedic physicians to distribute Progenza™knee OA cell therapy

• Includes upfront and milestones payments of US$19m, and single to double-digit royalties on product sale

• Kyocera responsible for product development, manufacturing, regulatory, and commercialisation processes in Japan

• Exclusivity for knee osteoarthritis in Japan

• Entering into the agreement with Regeneus demonstrates Kyocera’s belief in the Progenza™technology

• Regeneus retains the right to negotiate licenses with parties within Japan for indications other than knee OA and outside of Japan for all indications

Accelerated timeline to Conditional Approval

==> picture [491 x 125] intentionally omitted <==

----- Start of picture text -----

License
Comprehensive DD and
Agreement Tech transfer GMP Final Product manufacturing
negotiations
signed
PD, nonclinical work
2018 Aug-20 Apr-21 Sep-21 mid-22
----- End of picture text -----

==> picture [732 x 122] intentionally omitted <==

----- Start of picture text -----

License PMDA
Agreement Tech transfer GMP Final Product manufacturing Phase 2 trial Conditional
signed Approval
PD, nonclinical work
Aug-20 Apr-21 Sep-21 mid-22 2023 2024
----- End of picture text -----

==> picture [130 x 21] intentionally omitted <==

Confidential

20

Progenza™osteoarthritis opportunity in United States

==> picture [33 x 32] intentionally omitted <==

Regeneus plans to initiate a Phase 2 trial in the US in 2022

Market opportunity

US osteoarthritis therapeutics market (USD bn)

US osteoarthritis patients

==> picture [778 x 246] intentionally omitted <==

----- Start of picture text -----

75% of
global OA
market
33 million
CAGR:
9.1%
2.6
1 in 7
adults
1.1
2016 2026
----- End of picture text -----

==> picture [74 x 7] intentionally omitted <==

----- Start of picture text -----

Source: GlobalData
----- End of picture text -----

Source: Osteoarthritis Action Alliance

==> picture [130 x 21] intentionally omitted <==

Confidential

21

Expected Progenza™osteoarthritis US Phase 2 trial timeline

==> picture [33 x 32] intentionally omitted <==

	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2022	2022	2022	2022	2022	2022	2022	2022	2022	2022	2022	2022	2023	2023	2023	2023	2023	2023	2023	2023	2023	2023	2023	2023
month	2	3	4	5	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12
Regulatory GAP analysis
FDA Pre-IND Meeting
NIH grant funding process
Non-GMP product
Nonclinical study
GMP product available
IND submission
IRB approval
Recruitment
Follow-up period
Initial read-outs

Regulatory Financial CMC Nonclinical Clinical

==> picture [130 x 21] intentionally omitted <==

Confidential

22

Other near term value accreting opportunities

==> picture [33 x 33] intentionally omitted <==

Product	Geography	Stage	Indication	Status	Timing
Progenza	Australia	Phase 2	Knee osteoarthritis	• Similar clinical trial design to the Progenza OA Phase 2 trial in the US • Ability to use the same Progenza cGMP product as in the US • A grant application to fund the trial is being reviewed by the NHMRC	Q2 2021
Sygenus	Australia	Phase 1	Pain	• Phase 1 trial with human subjects in a pain indication	Q2 2021

==> picture [130 x 21] intentionally omitted <==

Confidential

23

Regeneus investment highlights

Leading, differentiated technology platform	• A unique combination of stem cells and their bioactive secretome exerts superior therapeutic effect • Applicable in a broad range of pain and inflammation indications • A scalable and cost effective manufacturing process • IP has been developed and is fully owned by Regeneus
Attractive market potential	• Global pain management market is a growing and significant multi billion-dollar opportunity • Large unmet market need for disease-modifying therapeutics in osteoarthritis • Secular tailwinds in the osteoarthritis market – ageing population and increasing prevalence of obesity
ProgenzaTM OA Phase 2 ready asset	• Progenza OA is a Phase 2 ready asset with strong nonclinical and Phase 1 data — validated by Kyocera during the extensive technology due diligence process • Active pipeline of potential licensing opportunities in key geographies
Near term value accreting opportunities	• Kyocera partnership to deliver additional US$13m in milestone payments in the next 3-4 years • Opportunities beyond osteoarthritis in Japan: — Progenza OA Phase 2 trial in the United States (2022) — Progenza OA Phase 2 trial in Australia (2022) — Sygenus Pain Phase 1 trial in Australia (2021)

==> picture [130 x 21] intentionally omitted <==

Confidential

24

Contact details

karolis.rosickas@regeneus.com www.regeneus.com

Regeneus Ltd

2 Paddington Street Paddington, NSW 2021 Australia

==> picture [32 x 32] intentionally omitted <==

/regeneus-ltd

==> picture [32 x 33] intentionally omitted <==

@regeneus /regeneus

==> picture [32 x 32] intentionally omitted <==

==> picture [334 x 336] intentionally omitted <==

==> picture [129 x 21] intentionally omitted <==

25